A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Delcath Systems, Inc.
Start Date
March 1, 2016
End Date
February 28, 2022
Administered By
Duke Cancer Institute
Awarded By
Delcath Systems, Inc.
Start Date
March 1, 2016
End Date
February 28, 2022